. | Geometric mean . | . | . | . | . | . | Point estimate (95% confidence limits)^{*}. | . | . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

. | All . | . | Children . | . | Adolescents . | . | All . | Adolescents/children . | . | |||||||

. | Glu . | RHI . | Glu . | RHI . | Glu . | RHI . | Glu/RHI . | Glu . | RHI . | |||||||

n | 20 | 19 | 10 | 10 | 10 | 9 | 19 | 10 | 9 | |||||||

INS AUC_{(0–1h)} (μIU · min^{−1} · ml^{−1}) | 2,287 | 1,246 | 2,170 | 1,023 | 2,410 | 1,552 | 176% (127, 244) | 111% (70, 175) | 152% (89, 258) | |||||||

INS AUC_{(0–2h)} (μIU · min^{−1} · ml^{−1}) | 5,232 | 2,994 | 4,948 | 2,383 | 5,534 | 3,860 | 169% (127, 224) | 112% (72, 174) | 162% (105, 250) | |||||||

INS AUC_{(0–4h)} (μIU · min^{−1} · ml^{−1}) | 7,624 | 5,703 | 7,193 | 4,530 | 8,081 | 7,367 | 130% (99, 170) | 112% (72, 175) | 163% (111, 238) | |||||||

INS AUC_{(0–6h)} (μIU · min^{−1} · ml^{−1}) | 8,361 | 7,052 | 7,934 | 5,581 | 8,811 | 9,145 | 116% (90, 150) | 111% (73, 169) | 164% (114, 236) | |||||||

C_{max} (μIU/ml) | 58 | 33 | 55 | 25 | 61 | 44 | 171% (127, 229) | 112% (73, 172) | 177% (112, 281) | |||||||

t_{max} (min) | 54^{†} | 66^{†} | 55^{†} | 59^{†} | 52 | 76^{†} | −8 min (−24, 7)^{‡} | −2 min (−9, 11) | 9 min (−24, 49) | |||||||

MRT (min) | 88 | 137 | 87 | 132 | 90 | 144 | 64% (59, 70) | 103% (88, 121) | 110% (92, 130) |

. | Geometric mean . | . | . | . | . | . | Point estimate (95% confidence limits)^{*}. | . | . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

. | All . | . | Children . | . | Adolescents . | . | All . | Adolescents/children . | . | |||||||

. | Glu . | RHI . | Glu . | RHI . | Glu . | RHI . | Glu/RHI . | Glu . | RHI . | |||||||

n | 20 | 19 | 10 | 10 | 10 | 9 | 19 | 10 | 9 | |||||||

INS AUC_{(0–1h)} (μIU · min^{−1} · ml^{−1}) | 2,287 | 1,246 | 2,170 | 1,023 | 2,410 | 1,552 | 176% (127, 244) | 111% (70, 175) | 152% (89, 258) | |||||||

INS AUC_{(0–2h)} (μIU · min^{−1} · ml^{−1}) | 5,232 | 2,994 | 4,948 | 2,383 | 5,534 | 3,860 | 169% (127, 224) | 112% (72, 174) | 162% (105, 250) | |||||||

INS AUC_{(0–4h)} (μIU · min^{−1} · ml^{−1}) | 7,624 | 5,703 | 7,193 | 4,530 | 8,081 | 7,367 | 130% (99, 170) | 112% (72, 175) | 163% (111, 238) | |||||||

INS AUC_{(0–6h)} (μIU · min^{−1} · ml^{−1}) | 8,361 | 7,052 | 7,934 | 5,581 | 8,811 | 9,145 | 116% (90, 150) | 111% (73, 169) | 164% (114, 236) | |||||||

C_{max} (μIU/ml) | 58 | 33 | 55 | 25 | 61 | 44 | 171% (127, 229) | 112% (73, 172) | 177% (112, 281) | |||||||

t_{max} (min) | 54^{†} | 66^{†} | 55^{†} | 59^{†} | 52 | 76^{†} | −8 min (−24, 7)^{‡} | −2 min (−9, 11) | 9 min (−24, 49) | |||||||

MRT (min) | 88 | 137 | 87 | 132 | 90 | 144 | 64% (59, 70) | 103% (88, 121) | 110% (92, 130) |

*

Point estimates (95% confidence limits) for the ratio of treatment means.

†

Median;

‡

point estimates (95% confidence limits) for the respective median differences from nonparametric data analysis. Glu, glulisine.

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.